Patient Derived Cancer Models  >  Melanoma Cell Lines
 

451Lu Viable Cells (1 x 10^6 cells)

JCYIA Product
Order Offline
Number:
451Lu-01-0001
Size:
1 mL
Price:
$499.00
Shipping:
$41.00
Handling:
$20.00
Availability:
Ships next business day.

451Lu Viable Cells (1 x 10^6 cells) Properties

Description
451Lu Viable Cells - 451Lu-01-0001
Cell Line
Human Melanoma
Species of Origin
Human
Physical State
Frozen Cell Suspension
Shipping Condition
Dry Ice
Label
Concentration
1x10^6 Count By Hemocytometer
Buffer
None
Preservative
None
Stabilizer
None
Stage
Metastasis
BRAF
V600E
PTEN
WT
NRAS
WT
CKIT
WT
CDK4
WT
Tumorigenicity
Yes
Paired
Yes
Patient ID
1001
Cell Line Product Type
Viable Cells
Cell Viability
Yes
Medium
Tumor Specialized Media with 2% FBS
Subculture
Cells should be maintained between 30 – 95% confluence in tumor specialized medium with 2% FBS; split cultures 1:10 every 5-6 days using 0.25% trypsin/EDTA.
Incubation
36°C with 5% CO2
Download CofA:
Lot#  
Print

451Lu Viable Cells (1 x 10^6 cells) Description

Background
451Lu is a selected xenograft aggressive metastatic sub-line of WM164. WM164 is a metastatic human melanoma cell line established from a metastatic site (right upper arm) in a 22-year-old male with stage IV superficial spreading melanoma. 451Lu cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line is wild type for PTEN, N-RAS, c-KIT, and CDK4 genes.
Synonyms
Melanoma, patient derived tumor, tumor models, skin cancer, xenograft
Storage Condition
Cells are frozen with 90% FBS/10% DMSO solution at about 1x10^6 cells/ml. Store vial in liquid nitrogen upon arrival.
Application Note
The key applications of these cell lines include genetic studies, xenograft production, drug testing, and drug target discovery. These cell line models can be used in various biological assays, and for identifying critical target genes, and cell signaling pathways.
Purity/Specifity
Cells are sterile, validated by short tandem repeat profiling, and are tested as negative for mycoplasma. It is recommended that cell lines are tested for mycoplasma contamination and short tandem repeat (STR) profiling every 10 passages or each time a frozen seed stock is made. See cell culture protocol for additional details.
Disclaimer Note-Human
No test method can provide total assurance that the hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or any other infectious agents are absent. Thus, all blood products, including purified proteins derived from human blood sources, should be handled at Biosafety Level 2 as recommended by the CDC\NIH manual entitled Biosafety in Microbiological and Biomedical Laboratories for potentially infectious human serum, blood specimens or proteins derived from same. Source material for the human blood product supplied to your facility has been tested for the detection of HIV antibody, Hepatitis B surface antigen, antibody to Hepatitis C, HIV 1 antigen(s), antibody to HTLV - I/II, and syphilis by FDA guidelines. All units were found to be non-reactive/negative for these tests. All human blood source material is collected in FDA licensed centers and is tested with FDA approved test kits.
Disclaimer Note-General
Cell Line Limited Use License Required. THIS PRODUCT IS SUBJECT TO AN END-USER LICENSE AGREEMENT (EULA). BY ACCEPTING THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF USE SET FORTH BELOW and SET FORTH IN THE EULA. THIS PRODUCT IS FOR IN VITRO RESEARCH USE ONLY. THERAPEUTIC, DIAGNOSTIC, OR VETERINARY USE IS PROHIBITED. This product may not be resold or transferred by the recipient and may be used only by the recipient, in the recipient’s facility and only for research use and other uses specifically permitted by the EULA. No other commercial use is allowed. “Commercial Use” means any and all uses of this product by recipient or others for monetary or other consideration, including providing services, supplying information or data to unaffiliated third parties, and resale or transfer of this product for any use. Recipient has no right to modify, derivatize, genetically engineer or otherwise create variations of this product or associated cells or cell lines. ROCKLAND AND WISTAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. The terms set forth herein and in the EULA shall be governed by the laws of the Commonwealth of Pennsylvania, USA. To obtain a COMMERCIAL USE license for this product, please contact Rockland Immunochemicals, Inc. Please contact a technical service representative for more information. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
General Reference
Greshock J, Nathanson K, Martin AM, Zhang L, Coukos G, Weber BL, Zaks TZ. (2007) Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Cancer Res. 2007 Apr 15; 67(8):3594-600. Barretina J, Caponigro G, Stransky N. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012 Mar 28; 483 (7391): 603-607. doi: 10.1038/nature11003. Lin WM, Baker AC, Beroukhim R. (2008) Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 1; 68(3): 664-673. Doi: 10.1158/0008-5472.
Log in to submit your product review.


Product Type
Molecular Biology Reagents;
Catalog Number
MB-006

Product Type
Molecular Biology Reagents;
Catalog Number
MB-009-1000

Product Type
Molecular Biology Reagents;
Catalog Number
MB-017

Product Label

 

Description
Unconjugated
Color
Conjugation Reference
Molecular Weight
Excitation Wavelength
Conjugation Chemistry